← Leaderboards
Dayanidhi Raman
University Of Toledo Health Sci Campus
$3,139,036
Attributed
$3,263,726
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,263,726 · 3
By mechanism
R01$2,500,438 · 1
R21$763,288 · 2
Top collaborators
- Dipali Sharma1 shared
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroMediatingResistanceBreast Cancer CellMalignant Breast NeoplasmStemnessNeoplasm MetastasisTriple-Negative Invasive Breast CarcinomaTranscription FactorMortalityBreast Cancer PatientTumorSurvival RateCellsProteinsDrug ResistanceHelicaseCyclin D3Abcg2 GeneDistant MetastasisMouse ModelChemoresistanceMcl1 GeneKnock-Down
Grant awards (10)
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells$1,053,488
R01 · FY2025 · CA · contact PI
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells$388,292
R01 · FY2024 · CA · contact PI
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells$249,381
R01 · FY2024 · CA · contact PI
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells$400,551
R01 · FY2023 · CA · contact PI
Targeting of eIF4A along with immunotherapy to overcome chemoresistance$176,961
R21 · FY2023 · CA · contact PI
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells$408,726
R01 · FY2022 · CA · contact PI
Targeting of eIF4A along with immunotherapy to overcome chemoresistance$216,686
R21 · FY2022 · CA · contact PI
An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer$164,756
R21 · FY2017 · CA · contact PI
An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer$197,708
R21 · FY2016 · CA · contact PI
An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer$7,177
R21 · FY2016 · CA · contact PI